About GRAND PHARMA Company

The Group is an international pharmaceutical enterprise with innovative technology. Its core business spans the three major fields of nuclear drug anti-tumor diagnosis and treatment, precise cardiovascular and cerebrovascular interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. The Group is based on the pharmaceutical and biological industries, with patients' needs as the core, scientific and technological innovation as the driving force, increasing investment in innovative global products and advanced technology, enriching and improving the product pipeline, consolidating and strengthening the industrial chain layout, giving full play to the Group's industrial advantages and R&D capabilities, and providing more advanced and diverse treatment plans for patients around the world. Through unremitting efforts in recent years, the Group's development foundation has been more stable, the scale of operation has been consolidated, the business structure has been gradually optimized, the business methods have continued to improve, the pace of transformation and upgrading has accelerated, and the innovative layout has blossomed more. The Group's profitability continues to increase, contributing to R&D innovation; good mergers and acquisitions and integration capabilities to continue to consolidate the scale of development; integration of raw materials and formulations to improve the industrial chain structure; and diversification of business and entities to effectively strengthen comprehensive advantages. “Steady growth, strong innovation, and seeking solutions”, the Group will continue to adhere to the development concept of “comprehensive advantage, innovation leadership and global expansion”, adopt the strategy of “independent research and development and global expansion of two-wheel drive, global operation layout and dual cycle operation development” to form a new pattern of dual cycle linkage development and mutual promotion at home and abroad, and strive to become a technology-innovative international pharmaceutical enterprise respected by doctors and patients and returned to society.